Biomea Fusion Inc. announced that the FDA granted Fast Track designation to its lead investigational drug, BMF-219, for an undisclosed type of solid tumor.
The designation is intended to facilitate development and expedite review of drugs for serious conditions with unmet medical needs. It allows more frequent meetings with the FDA and may make BMF-219 eligible for accelerated approval and priority review, potentially shortening the time to reach patients.